The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374–1403.
   PubMed Web of Science ®Google Scholar
• Prat J. New insights into ovarian cancer pathology. Ann Oncol 2012;23(Suppl 10):x111–x117.
   PubMedGoogle Scholar
• Ricciardelli C, Oehler MK. Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 2009;62(3):270–275.
   PubMed Web of Science ®Google Scholar
• Sopik V, Iqbal J, Rosen B, Narod SA. Why have ovarian cancer mortality rates declined? Part I. Incidence. Gynecol Oncol 2015a;138(3, Sep):741–749.
   PubMed Web of Science ®Google Scholar
• Sopik V, Rosen B, Giannakeas V, Narod SA. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecol Oncol 2015b;138(3):757–61.
   PubMed Web of Science ®Google Scholar
• World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food N, Physical Activity, and the Prevention of Ovarian Cancer 2014. Available from http://www.dietandcancerreport.org/cup/cup_resources.php
   Google Scholar
• Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v23–v30.
   PubMedGoogle Scholar
• National_Comprehensive_Cancer_Network. Epithelial Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer), version 3.2012. Fort Washington, PA: NCCN; 2012.
   Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014;384(9951):1376–1388.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Karakasis K, Kohn EC, Oza AM. Ovarian cancer treatment: the end of empiricism? Cancer 2015;121(18):3203–3211..
   PubMed Web of Science ®Google Scholar
• Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas 2014;77(2):128–136.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Eisenhauer EL, Herzog TJ. Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs 2015;20(2):331–346.
   PubMed Web of Science ®Google Scholar
• Morotti M, Becker CM, Menada MV, Ferrero S. Targeting tyrosine-kinases in ovarian cancer. Expert Opin Investig Drugs 2013;22(10):1265–1279.
   PubMed Web of Science ®Google Scholar
• Vergoulidou M. More than a decade of tyrosine kinase inhibitors in the treatment of solid tumors: what we have learned and what the future holds. Biomark Insights 2015;10(Suppl 3):33–40.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012;31(1–2):143–162.
   PubMed Web of Science ®Google Scholar
• Gomez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D, Redondo A. Angiogenesis and ovarian cancer. Clin Transl Oncol 2009;11(9):564–571.
   PubMed Web of Science ®Google Scholar
• Hui G, Meng M. Prognostic value of vascular endothelial growth factor expression in women with ovarian cancer: a meta-analysis. J BUON 2015;20(3):870–878.
   PubMed Web of Science ®Google Scholar
• du Bois A, Kristensen G, Ray Coquard I, Reuss A, Pignata S, Colombo N EA. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOTintergroup phase III trial of standard frontline chemotherapy+/− nintedanib for advanced ovarian cancer. Int J Gynaecol Cancer 2013;2013:23.
   Google Scholar
• Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McneishI, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29(28):3798–3804.
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Berger R, Sella A, Sikic BI, Shen X, Ramies DA, et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients: results from a phase 2 randomized discontinuation trial (RDT). J Clin Oncol 2011;29:2011 ( suppl; abstr 5008).
   PubMed Web of Science ®Google Scholar
• Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, et al. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol 2015;138(1):55–61.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27(33):5601–5606.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Perren TJ, Raja Fa, Embleton A, Rustin GJS, Al JGE. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Amsterdam: European Cancer Congress (ECCO-ESMOESTRO); 2013.
   Google Scholar
• Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, FlemingGF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, et al. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129(1):86–91.
   PubMed Web of Science ®Google Scholar
• Bodnar L, Gornas M, Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 2011;123(1):33–36.
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Scambia G, Kim BG, Lhomme C, MarkowskaJ, Ray-CoquardI, et al.A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013;130(1):25–30.
   PubMed Web of Science ®Google Scholar
• Kohn EC, Lee J, Annunziata CM, Minasian LM, Zujewski J, Prindiville SA, et al. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naïve epithelial ovarian cancer (EOC) patients. J. Clin. Oncol. 2011;29 [Abstract 5019].
   Google Scholar
• Matei D, Sill MW, Lankes HA, Degeest K, Bristow RE, Mutch D, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011;29(1):69–75.
   PubMed Web of Science ®Google Scholar
• Pölcher M, Eckhardt M, Coch C, WolfgartenM, KublerK, HartmannG, et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 2010;66(1):203–207.
   PubMed Web of Science ®Google Scholar
• Ramasubbaiah R, Perkins SM, Schilder J, Whalen C, Johnson CS, Callahan M, et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 2011;123(3):499–504.
   PubMed Web of Science ®Google Scholar
• Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, MacalpineK, et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 2010;20(5):787–793.
   PubMed Web of Science ®Google Scholar
• Baumann KH, Du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol 2012;23(9):2265–2271.
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011;22(2):335–340.
   PubMed Web of Science ®Google Scholar
• Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, PereiraL, et al. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol 2013;128(2):215–220.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014;32(30):3374–3382.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32–37.
   PubMed Web of Science ®Google Scholar
• Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol 2015;16(5):561–568.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 2010;16(2):664–672.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ et al. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 2014;50(9):1638–1648.
   PubMed Web of Science ®Google Scholar
• Sahade M, Caparelli F, Hoff PM. Cediranib: a VEGF receptor tyrosine kinase inhibitor. Future Oncol 2012;8(7):775–781.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F et al. Nintedanib: from discovery to the clinic. J Med Chem 2015;58(3):1053–1063.
   PubMed Web of Science ®Google Scholar
• Davidson BA, Secord AA. Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. Int J Womens Health 2014;6:289–300.
   PubMedGoogle Scholar
• Jovelet C, Benard J, Forestier F, Farinotti R, Bidart JM, Gil S. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. Eur J Pharm Sci 2012;46(5):484–491.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005;1(2):221–234.
   PubMedGoogle Scholar
• Gui T, Shen K. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol 2012;36(5):490–496.
   PubMed Web of Science ®Google Scholar
• Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011;104(8):1241–1245.
   PubMed Web of Science ®Google Scholar
• Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 2005;23(24):5597–5604.
   PubMed Web of Science ®Google Scholar
• Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol 2010;119(3):451–456.
   PubMed Web of Science ®Google Scholar
• Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 2010;16(21):5320–5328.
   PubMed Web of Science ®Google Scholar
• Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005;15(5):785–792.
   PubMed Web of Science ®Google Scholar
• Hirte H, Oza A, Swenerton K, Ellard SL, Grimshaw R, Fisher B, et al. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol 2010;118(3):308–312.
   PubMed Web of Science ®Google Scholar
• Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008;110(1):49–55.
   PubMed Web of Science ®Google Scholar
• Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol 2014;32(4):320–326.
   PubMed Web of Science ®Google Scholar
• Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, et al. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol 2010;116(2):157–162.
   PubMed Web of Science ®Google Scholar
• Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007;109(7):1323–1330.
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 2005;11(15):5539–5548.
   PubMed Web of Science ®Google Scholar
• Wagner U, Du Bois A, Pfisterer J, Huober J, Loibl S, Luck HJ, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy—a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007;105(1):132–137.
   PubMed Web of Science ®Google Scholar
• Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 2012;124(3):569–574.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, et al. Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial. Int J Gynecol Cancer 2012;22(9):1483–1488.
   PubMed Web of Science ®Google Scholar
• Rivkin SE, Muller C, Iriarte D, Arthur J, Canoy A, Reid H. Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients. J Clin Oncol 2008;26(15S(May 20 supplement)):5556.
   Google Scholar
• Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 2011;122(1):116–120.
   PubMed Web of Science ®Google Scholar
• Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res 2010;180:103–114.
   PubMedGoogle Scholar
• Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, et al. Platelet-derived growth factor receptor alpha (PDGFRalpha) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol 2014;132(1):166–175.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Wilczynski SP, Jang A, Moon J, Ward JH, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007;17(4):784–788.
   PubMed Web of Science ®Google Scholar
• Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer 2008;113(4):723–732.
   PubMed Web of Science ®Google Scholar
• Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol 2012;125(3):640–645.
   PubMed Web of Science ®Google Scholar
• Safra T, Andreopoulou E, Levinson B, Borgato L, Pothuri B, Blank S, et al. Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): Tolerance and activity in recurrent epithelial ovarian cancer. Anticancer Res 2010;30(9):3243–3247.
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2008;26(20):3418–3425.
   PubMed Web of Science ®Google Scholar
• Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist 2011;16(5):566–578.
   PubMed Web of Science ®Google Scholar
• Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003;88(1):73–79.
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, et al. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012;127(1):70–74.
   PubMed Web of Science ®Google Scholar
• Mcneish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M, et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancerdagger. Ann Oncol 2014;25(10):1988–1995.
   PubMed Web of Science ®Google Scholar
• Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9(3):167–181.
   PubMed Web of Science ®Google Scholar
• Yap TA, Sandhu SK, Workman P, De Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10(7):514–523.
   PubMed Web of Science ®Google Scholar
• Gasparri ML, Savone D, Besharat RA, Farooqi AA, Bellati F, Ruscito I, et al. Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer. Tumour Biol 2016;37(1):71–75. doi:10.1007/s13277-015-4299-9
   PubMed Web of Science ®Google Scholar
• Lheureux S, Oza AM. Targeting the microenvironment in ovarian cancer. Lancet Oncol 2015;16(5):485–486.
   PubMed Web of Science ®Google Scholar
• Jackson A, Davenport S, Herzog T, Coleman R. Targeting angiogenesis: vascular endothelial growth factor and related signaling pathways. Transl Cancer Res 2015;4(1):70–83.
   Web of Science ®Google Scholar
• Damaraju VL, Kuzma M, Mowles D, Cass CE, Sawyer MB. Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy? Mol Cancer Ther 2015;14(1):236–245.
   PubMed Web of Science ®Google Scholar
• Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010;11(5):465–475.
   PubMed Web of Science ®Google Scholar